Paper42577451
Identification of LILRB4 as a regulator of M2c macrophages and a potential immunotherapeutic target in ovarian cancer.
Zhou H and 5 others. Front Immunol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Identification of LILRB4 as a regulator of M2c macrophages and a potential immunotherapeutic target in ovarian cancer. Papers, record 42577451. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42577451
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Identification of LILRB4 as a regulator of M2c macrophages and a potential immunotherapeutic target in ovarian cancer.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ovarian Neoplasms | Major topic |
| Receptors, Immunologic | Major topic |
| Macrophages | Major topic |
| Membrane Glycoproteins | Major topic |
| Tumor-Associated Macrophages | Major topic |
| Female | |
| Humans | |
| Animals | |
| Cell Line, Tumor | |
| Tumor Microenvironment | |
| Mice | |
| Immunotherapy | |
| Gene Expression Regulation, Neoplastic | |
| Cell Proliferation | |
| Signal Transduction |
Source PubMed
References50
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39569201 | Mechanisms and treatment of atherosclerosis: focus on macrophages. | Front Immunol | 2024 | https://conductscience.org/library/papers/39569201 | PubMed |
| 2 | 38813706 | LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma. | Haematologica | 2024 | https://conductscience.org/library/papers/38813706 | PubMed |
| 3 | 39842553 | LILRB4 as a novel immunotherapeutic target for multiple diseases. | Biochem Pharmacol | 2025 | https://conductscience.org/library/papers/39842553 | PubMed |
| 4 | 37290427 | Prognostic impact of LILRB4 expression on tumor-infiltrating cells in resected non-small cell lung cancer. | Thorac Cancer | 2023 | https://conductscience.org/library/papers/37290427 | PubMed |
| 5 | 40690248 | Ovarian Cancer: A Review. | JAMA | 2025 | https://conductscience.org/library/papers/40690248 | PubMed |
| 6 | 40048761 | LILRB4 specific overexpression in myeloid cells promotes tumor progression and immunosuppression in mouse models. | Biochem Biophys Res Commun | 2025 | https://conductscience.org/library/papers/40048761 | PubMed |
| 7 | 35174213 | Overexpressed CMTM6 Improves Prognosis and Associated With Immune Infiltrates of Ovarian Cancer. | Front Mol Biosci | 2022 | https://conductscience.org/library/papers/35174213 | PubMed |
| 8 | 39232212 | Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach. | Nat Rev Clin Oncol | 2024 | https://conductscience.org/library/papers/39232212 | PubMed |
| 9 | 25756512 | PTEN inhibits macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism. | Cancer Biol Ther | 2015 | https://conductscience.org/library/papers/25756512 | PubMed |
| 10 | 40349571 | Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review. | Cancer Treat Rev | 2025 | https://conductscience.org/library/papers/40349571 | PubMed |
| 11 | 35447518 | Multifunctional "ball-rod" Janus nanoparticles boosting Fenton reaction for ferroptosis therapy of non-small cell lung cancer. | J Colloid Interface Sci | 2022 | https://conductscience.org/library/papers/35447518 | PubMed |
| 12 | 41613134 | SLC40A1-mediated positive feedback loop with M1 macrophages suppresses epithelial ovarian cancer progression. | Front Immunol | 2025 | https://conductscience.org/library/papers/41613134 | PubMed |
| 13 | 41089676 | Reprogramming the immune microenvironment in lung cancer. | Front Immunol | 2025 | https://conductscience.org/library/papers/41089676 | PubMed |
| 14 | 39975548 | Polymorphisms in immunosuppression-related genes are associated with AML. | Front Immunol | 2025 | https://conductscience.org/library/papers/39975548 | PubMed |
| 15 | 33777950 | CXCL11 Correlates With Antitumor Immunity and an Improved Prognosis in Colon Cancer. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/33777950 | PubMed |
| 16 | 26707054 | Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. | Lancet | 2016 | https://conductscience.org/library/papers/26707054 | PubMed |
| 17 | 39896800 | Characterizing tumor biology and immune microenvironment in high-grade serous ovarian cancer via single-cell RNA sequencing: insights for targeted and personalized immunotherapy strategies. | Front Immunol | 2024 | https://conductscience.org/library/papers/39896800 | PubMed |
| 18 | 34586722 | Tumor-derived exosomal miR-19b-3p facilitates M2 macrophage polarization and exosomal LINC00273 secretion to promote lung adenocarcinoma metastasis via Hippo pathway. | Clin Transl Med | 2021 | https://conductscience.org/library/papers/34586722 | PubMed |
| 19 | 24936477 | Tumor-associated macrophages contribute to tumor progression in ovarian cancer. | Front Oncol | 2014 | https://conductscience.org/library/papers/24936477 | PubMed |
| 20 | 40777010 | Transglutaminase 2 regulates ovarian cancer metastasis by modulating the immune microenvironment. | Front Immunol | 2025 | https://conductscience.org/library/papers/40777010 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42959057 | Regulatory mechanism of M2d tumor-associated macrophage-derived exosomal apolipoprotein E on platinum resistance in ovarian cancer. | Front Oncol | 2026 | https://conductscience.org/library/papers/42959057 |
Source PubMed
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CCL5 | 6352 | PubTator's text mining | https://conductscience.org/library/genes/6352 | NCBI Gene |
| LILRB4 | 11006 | PubTator's text mining | https://conductscience.org/library/genes/11006 | NCBI Gene |
| RELA | 5970 | PubTator's text mining | https://conductscience.org/library/genes/5970 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42577451
GET https://conductscience.org/api/papers/v1/42577451/references?page=2